Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.
创建时间：
2016-01-15
